Bangalore, India -- (SBWIRE) -- 05/11/2018 -- Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2018, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline landscape.

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. Treatment includes NSAIDs, acetaminophen, blood transfusion and surgery.

Report Highlights
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 4, 2, 1 and 1 respectively.

Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 75 pages "Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2018" report covers Introduction, Report Coverage, Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Overview, Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Development, Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Assessment, Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Companies Involved in Therapeutics Development, Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Drug Profiles, Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects, Appendix. This report Covered Companies - Asklepion Pharmaceuticals LLC, AstraZeneca Plc, Bristol-Myers Squibb Co, Gilead Sciences Inc, Modus Therapeutics Holding AB, Novartis AG, NuvOx Pharma LLC, Pfizer Inc, Prolong Pharmaceuticals LLC, Seattle Genetics Inc.

For more information Visit at: https://www.drugpipeline.net/global-markets-direct/vaso-occlusive-crisis-associated-sickle-cell-disease-pipeline-review-h1-2018

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/interleukin-2-receptor-subunit-alpha-tac-antigen-or-p55-or-cd25-or-il2ra-1

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/heparanase-endo-glucoronidase-or-heparanase-1-or-hpse-or-ec-321166-pipeline-0

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.